查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2020118

产后忧郁症治疗市场规模、份额、成长及全球产业分析：按类型、应用和地区分類的洞察，2026-2034 年预测

Postpartum Depression Treatment Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 150 Pages | 商品交期: 请询问到货日

价格

产后忧郁症(PPD) 治疗市场的成长要素

由于人们对产后忧郁症（PPD）的认识不断提高、盛行率不断上升以及治疗方法的进步，全球产后忧郁症治疗市场正在迅速扩张。预计到2025年，该市场规模将达到1.1483亿美元，到2026年增长至1.6684亿美元，到2034年将达到13.7985亿美元，在预测期（2026-2034年）内，复合年增长率将高达30.22%。

产后忧郁症是一种严重的疾病，会影响怀孕期间或产后一年内的女性。其特征是持续的悲伤、焦虑和疲劳，全球约有10%至15%的女性受其影响。随着人们对孕产妇心理健康的日益关注，对有效治疗方法（包括药物治疗和心理咨商）的需求显着增加。

市场动态

主要成长要素

市场成长的主要驱动因素之一是全球产后忧郁症盛行率的上升。除了诊断率的增加，宣传宣传活动的扩大也促使更多女性寻求治疗。各国政府和医疗机构正积极透过各种措施和宣传活动来促进孕产妇心理健康。

另一个主要因素是神经科学和药物研究的进步。各公司正致力于开发创新药物和治疗方法。诸如祖拉诺酮等新药的问世，拓宽了治疗选择，并提高了药物的可及性。

此外，遗传倾向、忧郁症病史和社会经济压力等风险因素导致患者数量增加，进而推动了对治疗方案的需求。

新冠疫情的影响

新冠疫情在2020年和2021年对市场造成了特别负面的影响。治疗延误、诊断率下降以及临床试验中断都阻碍了市场成长。然而，随着医疗服务的重新开放以及人们对心理健康的日益关注，市场在2022年和2023年开始復苏。

市场趋势

塑造市场格局的关键趋势之一是将人工智慧（AI）融入诊断和治疗领域。研究人员正在开发人工智慧工具，以改善早期检测和患者照护。数位平台和行动应用程式也日益普及，帮助医护人员和患者更有效地管理症状。

此外，对心理健康技术的投入增加以及创新诊断工具的开发，预计将在未来几年加速市场成长。

細項分析

药物

在市场区隔中，这些药物被分为普瑞沙诺酮、祖拉诺酮和其他药物。普瑞沙诺酮占据了主导市场份额，因为它是首个核准用于治疗产后忧郁症的药物。

由于具有口服、成本低廉、使用方便等优势，祖拉诺酮类药物预计将呈现最高的成长率。该药物于2023年核准，标誌着扩大治疗可及性的一个重要里程碑。

透过行政途径

根据给药途径，市场可分为口服、注射和其他途径。口服给药因其便利性、安全性和较高的患者接受度而占据市场主导地位。口服药物的引入极大地提高了患者获得治疗的机会。

肠外给药领域也占据了相当大的份额，这得益于其能够提供快速的生理反应和持续的效果。

透过分销管道

市场区隔将市场分为医院药局和专科药局。由于住院患者数量的增加和处方笺治疗的扩展，医院药房占据市场主导地位。

随着各公司与分销合作伙伴合作，将药物直接送到患者手中，专业药房的发展势头日益强劲，从而提高了药物的可及性和用药依从性。

区域趋势

北美在产后忧郁症治疗市场占据主导地位，预计2025年将占全球市场份额的97.93%，市场规模达到1.1244亿美元。在较高的认知度、先进的医疗基础设施和强有力的监管支持的推动下，该地区预计到2026年市场规模将达到1.6303亿美元。

亚太地区是一个新兴市场，预计2025年市场规模为238万美元，2026年为381万美元。该地区的成长是由人们意识的提高、医疗保健投资的增加以及对孕产妇健康日益增长的兴趣所推动的。

包括欧洲和拉丁美洲在内的其他地区，由于政府主导的倡议和人们对心理健康护理日益增长的兴趣，也出现了逐步增长。

策略联盟、产品核准和研发投资仍是市场参与企业巩固自身地位的关键策略。

目录

第一章：引言

第二章执行摘要

第三章 市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场趋势

第四章：主要考虑因素

  • 2025/2025年主要国家及地区产后忧郁症盛行率
  • 主要企业管道分析
  • 主要国家/地区的法规和还款状况
  • 产业重大发展动态：併购与合作
  • 新冠疫情对全球产后忧郁症市场的影响

第五章：2021-2034年全球产后忧郁症治疗市场分析、洞察与预测

  • 市场分析、洞察与预测：按药物分类
    • 祖拉诺隆
    • 布瑞沙诺酮
    • 其他的
  • 市场分析、洞察与预测：按给药途径
    • 口服
    • 肠外
    • 其他的
  • 市场分析、洞察与预测：按分销管道划分
    • 医院药房
    • 专科药房
  • 市场分析、洞察与预测：按地区划分
    • 北美洲
    • 亚太地区
    • 世界其他地区

第六章：北美产后忧郁症治疗市场分析、洞察与预测（2021-2034年）

  • 国家
    • 我们
    • 加拿大

第七章：亚太地区产后忧郁症治疗市场分析、洞察与预测（2021-2034年）

  • 国家
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 其他亚太国家

第八章：2021-2034年全球产后忧郁症治疗市场分析、洞察与预测

第九章 竞争分析

  • 全球市占率分析（2025 年）
  • 公司简介
    • Sage Therapeutics, Inc.
    • Biogen Inc.
    • Brii Biosciences Limited
    • GH Research Ireland Limited
Product Code: FBI109264

Growth Factors of postpartum depression (PPD) treatment Market

The global postpartum depression (PPD) treatment market is experiencing rapid expansion due to increasing awareness, rising prevalence, and advancements in treatment options. The market was valued at USD 114.83 million in 2025 and is projected to grow to USD 166.84 million in 2026, reaching USD 1,379.85 million by 2034, exhibiting a remarkable CAGR of 30.22% during the forecast period (2026-2034).

Postpartum depression is a serious medical condition affecting women during pregnancy or within the first year after childbirth. It is characterized by prolonged sadness, anxiety, and fatigue, impacting nearly 10% to 15% of women globally. The growing recognition of maternal mental health has significantly increased demand for effective treatment solutions, including medications and counseling.

Market Dynamics

Key Growth Drivers

One of the primary drivers of market growth is the increasing prevalence of postpartum depression worldwide. Rising diagnosis rates, coupled with growing awareness campaigns, are encouraging more women to seek treatment. Governments and healthcare organizations are actively promoting maternal mental health through initiatives and awareness programs.

Another major factor is the advancement in neuroscience and pharmaceutical research. Companies are focusing on developing innovative drugs and therapies. The introduction of new medications, such as zuranolone, has expanded treatment options and improved accessibility.

Additionally, risk factors such as genetic predisposition, history of depression, and socio-economic stress are contributing to the growing patient population, thereby driving demand for therapeutic solutions.

Impact of COVID-19

The COVID-19 pandemic negatively impacted the market, particularly in 2020 and 2021. Delays in treatment, reduced diagnosis rates, and disruptions in clinical trials hindered growth. However, the market began recovering in 2022 and 2023 due to the resumption of healthcare services and increased focus on mental health.

Market Trends

A key trend shaping the market is the integration of artificial intelligence (AI) in diagnosis and treatment. Researchers are developing AI-based tools to improve early detection and patient care. Digital platforms and mobile applications are also gaining traction, helping healthcare providers and patients manage symptoms more effectively.

Furthermore, increased funding for mental health technologies and the development of innovative diagnostic tools are expected to accelerate market growth in the coming years.

Segmentation Analysis

By Drug

The market is segmented into brexanolone, zuranolone, and others. The brexanolone segment holds a dominant share as it was the first FDA-approved drug for postpartum depression.

The zuranolone segment is expected to grow at the fastest rate due to its advantages, including oral administration, lower cost, and ease of use. Its approval in 2023 marked a significant milestone in expanding treatment accessibility.

By Route of Administration

Based on administration, the market includes oral, parenteral, and others. The oral segment dominates due to convenience, safety, and higher patient acceptance. The introduction of oral drugs has revolutionized treatment accessibility.

The parenteral segment also holds a significant share, driven by its ability to provide rapid physiological response and long-lasting effects.

By Distribution Channel

The market is segmented into hospital pharmacies and specialty pharmacies. Hospital pharmacies lead the market due to increased hospitalization and prescription-based treatments.

Specialty pharmacies are gaining traction as companies collaborate with distribution partners to deliver medications directly to patients, improving accessibility and adherence.

Regional Insights

North America dominates the postpartum depression treatment market, accounting for 97.93% of the global share in 2025, with a market size of USD 112.44 million. The region is projected to reach USD 163.03 million in 2026, driven by high awareness, advanced healthcare infrastructure, and strong regulatory support.

Asia Pacific is an emerging market, valued at USD 2.38 million in 2025 and expected to reach USD 3.81 million in 2026. Growth in this region is attributed to increasing awareness, rising healthcare investments, and growing focus on maternal health.

Other regions, including Europe and Latin America, are also witnessing gradual growth due to government initiatives and increasing attention to mental health care.

Competitive Landscape

The market is highly consolidated, with key players such as Sage Therapeutics, Inc. and Biogen Inc. leading the industry. These companies are actively involved in drug development and commercialization of innovative therapies.

Emerging players such as Brii Biosciences Limited and GH Research Ireland Limited are also contributing through clinical trials and pipeline products, intensifying competition in the market.

Strategic partnerships, product approvals, and research investments remain key strategies adopted by market participants to strengthen their positions.

Conclusion

The postpartum depression treatment market is set for exponential growth, expanding from USD 114.83 million in 2025 to USD 1,379.85 million by 2034. This growth is driven by increasing awareness, rising disease prevalence, and continuous advancements in treatment technologies. While high treatment costs and limited drug availability pose challenges, ongoing innovation and supportive healthcare initiatives are expected to unlock significant opportunities. Overall, the market will play a critical role in improving maternal mental health outcomes globally in the coming years.

Segmentation By Drug

  • Zuranolone
  • Brexanolone
  • Others

By Route of Administration

  • Oral
  • Parenteral
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Specialty Pharmacies

By Region

  • North America (By Drug, Route of Administration, Distribution Channel, and Country/Sub-Region)
    • U.S.
    • Canada
  • Asia Pacific (By Drug, Route of Administration, Distribution Channel, and Country/Sub-Region)
    • China
    • Japan
    • India
    • Australia
    • Rest of the Asia Pacific
  • Rest of the World ( By Drug, Route of Administration, and Distribution Channel)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Postpartum Depression - By Key Countries/Regions, 2025/2025
  • 4.2. Pipeline Analysis, By Key Players
  • 4.3. Regulatory and Reimbursement Scenario, By Key Countries/Regions
  • 4.4. Key Industry Developments: Mergers, Acquisitions, and Partnerships
  • 4.5. Impact of COVID-19 on the Global Postpartum Depression Market

5. Global Postpartum Depression Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug
    • 5.1.1. Zuranolone
    • 5.1.2. Brexanolone
    • 5.1.3. Others
  • 5.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.2.1. Oral
    • 5.2.2. Parenteral
    • 5.2.3. Others
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Hospital Pharmacies
    • 5.3.2. Specialty Pharmacies
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Asia Pacific
    • 5.4.3. Rest of the World

6. North America Postpartum Depression Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug
    • 6.1.1. Zuranolone
    • 6.1.2. Brexanolone
    • 6.1.3. Others
  • 6.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.2.1. Oral
    • 6.2.2. Parenteral
    • 6.2.3. Others
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Hospital Pharmacies
    • 6.3.2. Specialty Pharmacies
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Asia Pacific Postpartum Depression Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug
    • 7.1.1. Zuranolone
    • 7.1.2. Brexanolone
    • 7.1.3. Others
  • 7.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.2.1. Oral
    • 7.2.2. Parenteral
    • 7.2.3. Others
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Hospital Pharmacies
    • 7.3.2. Specialty Pharmacies
  • 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.4.1. China
    • 7.4.2. Japan
    • 7.4.3. India
    • 7.4.4. Australia
    • 7.4.5. Rest of Asia Pacific

8. Rest of the World Postpartum Depression Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug
    • 8.1.1. Zuranolone
    • 8.1.2. Brexanolone
    • 8.1.3. Others
  • 8.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.2.1. Oral
    • 8.2.2. Parenteral
    • 8.2.3. Others
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Specialty Pharmacies

9. Competitive Analysis

  • 9.1. Global Market Share Analysis (2025)
  • 9.2. Company Profiles
    • 9.2.1. Sage Therapeutics, Inc.
      • 9.2.1.1. Overview
      • 9.2.1.2. Products & Services
      • 9.2.1.3. SWOT Analysis
      • 9.2.1.4. Recent Developments
      • 9.2.1.5. Strategies
      • 9.2.1.6. Financials (Based on Availability)
    • 9.2.2. Biogen Inc.
      • 9.2.2.1. Overview
      • 9.2.2.2. Products & Services
      • 9.2.2.3. SWOT Analysis
      • 9.2.2.4. Recent Developments
      • 9.2.2.5. Strategies
      • 9.2.2.6. Financials (Based on Availability)
    • 9.2.3. Brii Biosciences Limited
      • 9.2.3.1. Overview
      • 9.2.3.2. Products & Services
      • 9.2.3.3. SWOT Analysis
      • 9.2.3.4. Recent Developments
      • 9.2.3.5. Strategies
      • 9.2.3.6. Financials (Based on Availability)
    • 9.2.4. GH Research Ireland Limited
      • 9.2.4.1. Overview
      • 9.2.4.2. Products & Services
      • 9.2.4.3. SWOT Analysis
      • 9.2.4.4. Recent Developments
      • 9.2.4.5. Strategies
      • 9.2.4.6. Financials (Based on Availability)

List of Tables

  • Table 1:Global Postpartum Depression Treatment Market Revenue (USD million) Forecast, By Drug, 2021-2034
  • Table 2:Global Postpartum Depression Treatment Market Revenue (USD million) Forecast, By Route of Administration, 2021-2034
  • Table 3:Global Postpartum Depression Treatment Market Revenue (USD million) Forecast, By Distribution Channel, 2021-2034
  • Table 4:Global Postpartum Depression Treatment Market Revenue (USD million) Forecast, By Region, 2021-2034
  • Table 5:North America Postpartum Depression Treatment Market Revenue (USD million) Forecast, By Drug, 2021-2034
  • Table 6:North America Postpartum Depression Treatment Market Revenue (USD million) Forecast, By Route of Administration, 2021-2034
  • Table 7:North America Postpartum Depression Treatment Market Revenue (USD million) Forecast, By Distribution Channel, 2021-2034
  • Table 8:North America Postpartum Depression Treatment Market Revenue (USD million) Forecast, By Country, 2021-2034
  • Table 9:Asia Pacific Postpartum Depression Treatment Market Revenue (USD million) Forecast, By Drug, 2021-2034
  • Table 10:Asia Pacific Postpartum Depression Treatment Market Revenue (USD million) Forecast, By Route of Administration, 2021-2034
  • Table 11:Asia Pacific Postpartum Depression Treatment Market Revenue (USD million) Forecast, By Distribution Channel, 2021-2034
  • Table 12:Asia Pacific Postpartum Depression Treatment Market Revenue (USD million) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13:Rest of the World Postpartum Depression Treatment Market Revenue (USD million) Forecast, By Drug, 2021-2034
  • Table 14:Rest of the World Postpartum Depression Treatment Market Revenue (USD million) Forecast, By Route of Administration, 2021-2034
  • Table 15:Rest of the World Postpartum Depression Treatment Market Revenue (USD million) Forecast, By Distribution Channel, 2021-2034

List of Figures

  • Figure 1:Global Postpartum Depression Treatment Market Revenue Breakdown (USD million, %) By Region, 2025 & 2034
  • Figure 2:Global Postpartum Depression Treatment Market Value Share (%), By Drug, 2025 & 2034
  • Figure 3:Global Postpartum Depression Treatment Market Value Share (%), By Route of Administration, 2025 & 2034
  • Figure 4:Global Postpartum Depression Treatment Market Value Share (%), By Distribution Channel, 2025 & 2034
  • Figure 5:Global Postpartum Depression Treatment Market Value (USD million), By Region, 2025 & 2034
  • Figure 6:North America Postpartum Depression Treatment Market Value (USD million), By Drug, 2025 & 2034
  • Figure 7:North America Postpartum Depression Treatment Market Value Share (%), By Drug, 2025
  • Figure 8:North America Postpartum Depression Treatment Market Value (USD million), Route of Administration, 2025 & 2034
  • Figure 9:North America Postpartum Depression Treatment Market Value Share (%), By Route of Administration, 2025
  • Figure 10:North America Postpartum Depression Treatment Market Value (USD million), By Distribution Channel, 2025 & 2034
  • Figure 11:North America Postpartum Depression Treatment Market Value Share (%), By Distribution Channel, 2025
  • Figure 12:North America Postpartum Depression Treatment Market Value (USD million), By Country, 2025 & 2034
  • Figure 13:North America Postpartum Depression Treatment Market Value Share (%), By Country, 2025
  • Figure 14:Asia Pacific Postpartum Depression Treatment Market Value (USD million), By Drug, 2025 & 2034
  • Figure 15:Asia Pacific Postpartum Depression Treatment Market Value Share (%), By Drug, 2025
  • Figure 16:Asia Pacific Postpartum Depression Treatment Market Value (USD million), Route of Administration, 2025 & 2034
  • Figure 17:Asia Pacific Postpartum Depression Treatment Market Value Share (%), By Route of Administration, 2025
  • Figure 18:Asia Pacific Postpartum Depression Treatment Market Value (USD million), By Distribution Channel, 2025 & 2034
  • Figure 19:Asia Pacific Postpartum Depression Treatment Market Value Share (%), By Distribution Channel, 2025
  • Figure 20:Asia Pacific Postpartum Depression Treatment Market Value (USD million), By Country/ Sub-region, 2025 & 2034
  • Figure 21:Asia Pacific Postpartum Depression Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 22:Rest of the World Postpartum Depression Treatment Market Value (USD million), By Drug, 2025 & 2034
  • Figure 23:Rest of the World Postpartum Depression Treatment Market Value Share (%), By Drug, 2025
  • Figure 24:Rest of the World Postpartum Depression Treatment Market Value (USD million), By Route of Administration, 2025 & 2034
  • Figure 25:Rest of the World Postpartum Depression Treatment Market Value Share (%), By Route of Administration, 2025
  • Figure 26:Rest of the World Postpartum Depression Treatment Market Value (USD million), By Distribution Channel, 2025 & 2034
  • Figure 27:Rest of the World Postpartum Depression Treatment Market Value Share (%), By Distribution Channel, 2025
  • Figure 28:Global Postpartum Depression Treatment Market Share (%), By Company, 2025